Study | Underlying malignancy | No. of patients enrolled | Median OS (95% CI), month | HR (95% CI) | P value | No. of patients (safety) | FAE | SAE |
---|---|---|---|---|---|---|---|---|
Borghaei,2015 [6] | Lung cancer | 292 | 12.2(9.7–15.0) | 0.73(0.59–0.89) | 0.002 | 287 | 1 | 21 |
290 | 9.4(8.1–10.7) | 268 | 1 | 53 | ||||
Brahmer, 2015 [7] | Lung cancer | 135 | 9.2(7.3–13.3) | 0.59(0.44–0.79) | < 0.001 | 131 | 0 | 9 |
137 | 6.0(5.1–7.3) | 129 | 3 | 31 | ||||
Carbone, 2017 [8] | Lung cancer | 271 | 14.4(11.7–17.4) | 1.02(0.80–1.30) | NR | 267 | 2 | 46 |
270 | 13.2(10.7–17.1) | 263 | 3 | 48 | ||||
Ferris, 2016 [10] | Head and neck cancer | 240 | 7.5(5.5–9.1) | 0.70(0.51–0.96) | 0.01 | 236 | 2 | NR |
121 | 5.1(4.0–6.0) | 111 | 1 | NR | ||||
Kang, 2017 [9] | G/GJC | 330 | 5.3(4.6–6.4) | 0.63(0.51–0.78) | < 0.0001 | 330 | 5 | 33 |
163 | 4.1(3.4–4.9) | 161 | 2 | 8 | ||||
Motzer, 2015 [11] | Renal cancer | 410 | 25.0(21.8-not reached) | 0.73(0.57–0.93) | 0.002 | 406 | 0 | NR |
411 | 19.6(17.6–23.1) | 397 | 2 | NR | ||||
Robert, 2015 [12] | Melanoma | 210 | Not reached | 0.42(0.25–0.73) | < 0.001 | 206 | 0 | 19 |
205 | 10.8(9.3–12.1) | 205 | 0 | 18 | ||||
Weber, 2017 [13] | Melanoma | 453 | NR | NR | NR | 452 | 0 | NR |
453 | NR | NR | NR | 453 | 2 | NR | ||
Wolchok, 2017 [14] | Melanoma | 314 | Not reached | NR | NR | 313 | 2 | NR |
316 | 37.6(29.1-not reached) | NR | NR | 313 | 1 | NR | ||
315 | 19.9(16.9–24.6) | NR | NR | 311 | 1 | NR | ||
D’angelo, 2018 [15] | Sarcoma | 43 | 10.7(5.5–15.4) | NR | NR | 42 | 0 | 8 |
42 | 14.3(9.6-not reached) | NR | NR | 42 | 0 | 11 | ||
Long, 2018 [16] | Melanoma | 35 | NR | NR | NR | 35 | 0 | 16 |
25 | NR | NR | NR | 25 | 0 | 1 | ||
16 | NR | NR | NR | 16 | 0 | 2 | ||
Motzer, 2015 [19] | Renal cancer | 60 | 18.2 | NR | NR | 59 | 0 | NR |
54 | 25.5 | NR | NR | 54 | 0 | NR | ||
54 | 24.7 | NR | NR | 54 | 0 | NR | ||
Hamanishi, 2015 [18] | Ovarian cancer | 20 | 20.0 | NR | NR | 20 | 0 | 5 |
Hida, 2017 [29] | Lung cancer | 35 | 16.3(12.4–25.4) | NR | NR | 35 | 0 | 3 |
Kudo, 2017 [30] | Esophageal cancer | 65 | 10.8(7.4–13.3) | NR | NR | 65 | 0 | 10 |
Maruyama, 2017 [31] | Hodgkin lymphoma | 17 | NR | NR | NR | 17 | 0 | 6 |
Nishio, 2017 [32] | Lung cancer | 76 | 17.1(13.3–23.0) | NR | NR | 76 | 0 | 15 |
Overman, 2017 [33] | Colorectal cancer | 74 | NR | NR | NR | 74 | 0 | 9 |
Rizvi, 2015 [34] | Lung cancer | 117 | 8.2(6.1–10.9) | NR | NR | 117 | 2 | NR |
Yamazaiki, 2017 [35] | Melanoma | 24 | NR | NR | NR | 24 | 0 | 4 |
Younes, 2016 [36] | Hodgkin lymphoma | 80 | NR | NR | NR | 80 | 0 | 5 |